AsiaMedic Limited

350 Orchard Road #08-00 Shaw House Singapore 238868

Co. Registration No: 197401556E

www.asiamedic.com.sg



Press Release - For Immediate Release

AsiaMedic Wins Most Transparent Company Award (Runner-Up, Catalist Category) At SIAS Investors' Choice Awards 2012

Singapore, 4 October 2012 – SGX Catalist-listed AsiaMedic Limited ("AsiaMedic", "亚美德科医疗集团", or the "Group"), a growing premier healthcare provider in Asia, is proud to announce it was awarded the "Most Transparent Company Award (Runner-Up, Catalist Category)" at the Securities Investors Association (Singapore) ("SIAS") Investors' Choice Awards 2012 on 3 October 2012.

Organised by SIAS to encourage public-listed companies to be more transparent so as to help investors make informed decisions, the award selection this year is based on the ICB classification. Companies are first shortlisted using the SMU-SKBI Singapore Corporate Governance Index (SCGI), a balance weighted index covering 5 aspects in the OECD principles. The Most Transparent Company Award takes into consideration the "Disclosure and Transparency" aspect based on publicly available information and the company's performance.

Commenting on the accolade, Dr. Wong Weng Hong, CEO of AsiaMedic, said: "We are privileged to have received this award which recognises AsiaMedic's good corporate transparency and disclosure standards.

On behalf of the Board of Directors and management team, I would like to thank SIAS, the investing community and the media for their acknowledgement of AsiaMedic's efforts at upholding high corporate transparency standards and best practices.

Going forward, we are committed to actively engaging our stakeholders through timely and accurate communications. At the same time, as we expand our business footprint into China and Myanmar and raise our profile internationally, we will strive to continually deliver excellence across all our business divisions and further enhance the growth and value proposition for our stakeholders."

- END -

Media & Investor Contacts

Mr. Seah Han Mr. Andy Lin

Direct Line: +65 6517 8780 Direct Line: +65 6517 8775 Mobile: +65 8318 1820 Mobile: +65 9651 7743

About AsiaMedic Limited (Bloomberg: AMAT:SP / Reuters: ASIM.SI)

Headquartered in Singapore and listed on the Catalist Board of the Singapore Stock Exchange, AsiaMedic Limited is a premier healthcare provider that focuses on the management of clinical services in the fields of disease prevention, early illness detection and advanced diagnostics. Its team of highly qualified and reputable professionals provides clinical and management services both in Singapore and overseas.

The services provided by AsiaMedic include but are not limited to health-risk assessments and screening, general and subspecialty imaging such as MRI and CT Scans for cardiovascular, neuroradiological, ENT and musculoskeletal imaging; PET/CT imaging for diagnosis, staging, localisation and monitoring progress of cancer.

Driven by its commitment to the core values of competence, care, convenience and collaboration, AsiaMedic has built up a strong brand name for delivering positive patient outcomes and high-quality care for its patients from Singapore and around the region.

Apart from Singapore, AsiaMedic has a growing presence in key growth markets such as China, Indonesia, Vietnam and Russia. Recognising the increasing demand for quality healthcare services in Asia and the Middle East, AsiaMedic expanded into the provision of international healthcare consultancy and management services in 2009.

As an endorsement of its strengths and track record in the regional healthcare services industry, AsiaMedic was awarded two high-profiled turnkey projects in Abu Dhabi by Mubadala Healthcare, a division of Mubadala Development Co. and owned by the Government of the Emirate of Abu Dhabi. The projects were successfully completed and handed over in early 2012.

Having tested and proven its healthcare services business model in Singapore and the region, AsiaMedic is developing more innovative healthcare services in selected markets for its next stage of growth.